Alpine Woods Capital Investors LLC Takes Position in Seres Therapeutics Inc (MCRB)

Alpine Woods Capital Investors LLC acquired a new position in shares of Seres Therapeutics Inc (NASDAQ:MCRB) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 60,000 shares of the biotechnology company’s stock, valued at approximately $412,000. Alpine Woods Capital Investors LLC owned approximately 0.15% of Seres Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. BlackRock Inc. increased its stake in Seres Therapeutics by 1.8% during the 3rd quarter. BlackRock Inc. now owns 2,281,563 shares of the biotechnology company’s stock worth $17,318,000 after buying an additional 40,719 shares in the last quarter. Nikko Asset Management Americas Inc. increased its stake in Seres Therapeutics by 24,968.9% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 818,499 shares of the biotechnology company’s stock worth $5,623,000 after buying an additional 815,234 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Seres Therapeutics by 6.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 421,494 shares of the biotechnology company’s stock worth $3,199,000 after buying an additional 25,287 shares in the last quarter. D. E. Shaw & Co. Inc. increased its stake in Seres Therapeutics by 5.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 307,930 shares of the biotechnology company’s stock worth $1,392,000 after buying an additional 17,194 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Seres Therapeutics by 5.1% during the 4th quarter. Geode Capital Management LLC now owns 237,774 shares of the biotechnology company’s stock worth $1,074,000 after buying an additional 11,476 shares in the last quarter. Institutional investors own 79.26% of the company’s stock.

MCRB stock opened at $4.25 on Wednesday. The company has a market capitalization of $172.60 million, a PE ratio of -1.75 and a beta of 1.80. Seres Therapeutics Inc has a 1 year low of $4.13 and a 1 year high of $9.75.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.12). The company had revenue of $7.32 million during the quarter, compared to analysts’ expectations of $8.61 million. Seres Therapeutics had a negative net margin of 301.60% and a negative return on equity of 1,583.95%. As a group, sell-side analysts predict that Seres Therapeutics Inc will post -1.9 EPS for the current fiscal year.

Several equities research analysts have commented on the company. BidaskClub lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. HC Wainwright reiterated a “buy” rating on shares of Seres Therapeutics in a research note on Friday, February 22nd. ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 27th. Jefferies Financial Group initiated coverage on Seres Therapeutics in a research report on Tuesday, April 30th. They issued a “hold” rating and a $7.00 price target for the company. Finally, Cowen restated a “buy” rating on shares of Seres Therapeutics in a research report on Tuesday, May 7th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $11.13.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Rockland Register and is owned by of Rockland Register. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://rocklandregister.com/2019/05/15/alpine-woods-capital-investors-llc-takes-position-in-seres-therapeutics-inc-mcrb.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Further Reading: Beige Book

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.